Experimental cancer drug JSI-1187 tested in early trial

NCT ID NCT04418167

Terminated Disease control Sponsor: JS InnoPharm, LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called JSI-1187, alone or with another cancer drug (dabrafenib), in people with advanced solid tumors that have certain genetic changes. The main goal is to check safety and side effects. About 71 adults with tumors that have not responded to standard treatments are being enrolled. The trial is currently on hold.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JSI-1187 (an experimental drug) and dabrafenib (a targeted cancer drug)
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors with specific genetic mutations.
What could go wrong: This is a very early Phase 1 trial with only 71 participants, so it is primarily testing safety. The drug may not shrink tumors or could cause side effects. The trial is currently suspended, which raises caution.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAF V600E/K-MUTATED UNRESECTABLE OR METASTATIC MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma neoplasm non-small cell lung carcinoma thyroid gland undifferentiated (anaplastic) carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States
Mayo Clinic Cancer Center

Phoenix, Arizona, 85054, United States
Mayo Clinic Cancer Center

Jacksonville, Florida, 32224, United States
Mayo Clinic Cancer Center

Rochester, Minnesota, 55905, United States
University of Arizona Comprehensive Cancer Center

Tucson, Arizona, 85724, United States
University of California Helen Diller Family Comprehensive Cancer Center

San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.